Patent Allowance for GLIX1 Cancer Treatment
BioLineRx Ltd. (NASDAQ: BLRX) recently received a significant boost in its intellectual property with the issuance of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). This key patent focuses on GLIX1, a promising new treatment for various cancer types. The patent specifically targets conditions where cytidine deaminase (CDA) is not over-expressed, which is estimated to include over 90% of all cancer cases.
Strengthening Cancer Treatment Options
The allowed patent is an important development for BioLineRx as it enhances GLIX1's patent protection until at least 2040, with the potential for an additional five-year extension. This strategic move not only secures the company's innovative cancer treatment but also reflects their commitment to advancing healthcare solutions for patients facing daunting cancer diagnoses.
Expanding GLIX1's Applications
As BioLineRx ventures beyond glioblastoma—the initial cancer indication for GLIX1—the recent patent allowance opens doors for exploring treatment possibilities for other cancers. With over 90% of cancers not overexpressing CDA beyond the threshold, the company sees vast potential to broaden GLIX1's usage in future clinical applications.
CEO's Insights on the Milestone
Philip Serlin, the Chief Executive Officer of BioLineRx, emphasized the significance of the USPTO's Notice of Allowance for GLIX1. He stated, "This allows us to explore this exciting molecule across a vast range of cancer types. As we gear up to begin our first-in-human study for patients with glioblastoma in 2026, we're simultaneously advancing pre-clinical studies in different cancer models. We're optimistic about the potential of GLIX1 to provide hope for patients with challenging treatment-resistant cancers."
Comprehensive Patent Portfolio
GLIX1 is backed by a robust portfolio of patents, both granted and pending. Along with the newly allowed U.S. patent, BioLineRx is actively pursuing various international applications that support the use of GLIX1 in treating cancer—notably, both as a standalone monotherapy and in conjunction with well-established anti-cancer agents.
Areas of Coverage for GLIX1
The patents cover GLIX1 for treating central nervous system cancers, such as glioblastoma, with protections valid until at least 2040. Additionally, a pending international patent application seeks protection for its use in combination with PARP inhibitors for a majority of cancers, possibly extending patent validity until 2044.
About BioLineRx Ltd.
BioLineRx Ltd. is committed to developing life-changing therapies in oncology and rare diseases. Their first approved product, APHEXDA® (motixafortide), is indicated for stem cell mobilization. Currently, BioLineRx is collaborating with various partners to commercialize APHEXDA globally, while also retaining rights for further development in specific cancer treatments, including metastatic pancreatic cancer. Moreover, a joint venture with Hemispherian AS aims to push GLIX1 through clinical trials, expected to begin shortly.
Frequently Asked Questions
What is GLIX1 used for?
GLIX1 is a treatment aimed at various cancer types where CDA is not over-expressed, with potential applications expanding beyond glioblastoma.
What does the recent patent allow?
The patent allows BioLineRx to protect their intellectual property and pursue GLIX1's development for multiple cancer treatments until at least 2040.
When will clinical trials for GLIX1 begin?
The first-in-human study for GLIX1 is anticipated to start in the first quarter of 2026, focusing initially on glioblastoma patients.
How does GLIX1 work?
GLIX1 targets the DNA damage response in cancer cells, aiming to disrupt their growth and viability.
What other treatments does BioLineRx offer?
In addition to GLIX1, BioLineRx offers APHEXDA® (motixafortide) for stem cell mobilization in cancer patients, with ongoing studies in metastatic pancreatic cancer.
